顺铂敏感性/耐药性的分子基础。 - Suppr

Suppr

超能文献

The molecular basis of cisplatin sensitivity/resistance.

作者信息

Kelland L R

机构信息

Section of Drug Development, Institute of Cancer Research, Sutton, Surrey, U.K.

出版信息

Eur J Cancer. 1994;30A(6):725-7. doi: 10.1016/0959-8049(94)90281-x.

DOI:10.1016/0959-8049(94)90281-x

PMID:7917526

Abstract

摘要

相似文献

The molecular basis of cisplatin sensitivity/resistance.

Eur J Cancer. 1994;30A(6):725-7. doi: 10.1016/0959-8049(94)90281-x.

Assessment of platinum sensitivity in human tumor cells.

Int J Clin Pharmacol Ther. 2003 Dec;41(12):612-3. doi: 10.5414/cpp41612.

Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity.

Carcinogenesis. 1994 Sep;15(9):2053-6. doi: 10.1093/carcin/15.9.2053.

Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.

Cancer Res. 1992 Apr 1;52(7):1710-6.

Genetic basis of drug sensitivity in human testis tumour cells.

Int J Cancer. 1996 Feb 8;65(4):426-31. doi: 10.1002/(SICI)1097-0215(19960208)65:4<426::AID-IJC5>3.0.CO;2-Z.

Complementation analysis of testis tumor cells.

Cancer Genet Cytogenet. 1997 Oct 1;98(1):56-62. doi: 10.1016/s0165-4608(96)00398-6.

Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells.

Proc Natl Acad Sci U S A. 1988 Feb;85(3):650-3. doi: 10.1073/pnas.85.3.650.

Single step selection of cis-diamminedichloroplatinum(II) resistant mutants from a human ovarian carcinoma cell line.

Cancer Res. 1991 Apr 15;51(8):2242-5.

[Quantitative determination of dose-response relations of taxol and cisplatin in ovarian cancer cells with a bioassay in comparison with cytomorphology].

Gynakol Geburtshilfliche Rundsch. 1994;34(2):79-86. doi: 10.1159/000272342.

Metallothionein gene expression and resistance to cisplatin in human ovarian cancer.

Int J Cancer. 1990 Mar 15;45(3):416-22. doi: 10.1002/ijc.2910450306.

引用本文的文献

DFT Study on the Substituent Effect of Anticancer Picoline-Diazido-Pt(IV) Compounds.

Front Oncol. 2022 Jan 10;11:749178. doi: 10.3389/fonc.2021.749178. eCollection 2021.

Contributes to Cell Cycle Progression and Cisplatin Resistance.

Cancers (Basel). 2021 Aug 12;13(16):4066. doi: 10.3390/cancers13164066.

Trans labilization of am(m)ine ligands from platinum(II) complexes by cancer cell extracts.

J Biol Inorg Chem. 2009 Mar;14(3):387-99. doi: 10.1007/s00775-008-0456-6. Epub 2008 Dec 4.

Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei.

Nucleic Acids Res. 2006 Mar 29;34(6):e47. doi: 10.1093/nar/gkl051.

The trans labilization of cis-[PtCl2(13CH3NH2)2] by glutathione can be monitored at physiological pH by [1H,13C] HSQC NMR.

J Biol Inorg Chem. 2006 Mar;11(2):179-88. doi: 10.1007/s00775-005-0064-7. Epub 2005 Dec 10.

A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts.

Br J Cancer. 1999 Aug;80(12):1912-9. doi: 10.1038/sj.bjc.6690620.

Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin.

J Cancer Res Clin Oncol. 1996;122(10):603-12. doi: 10.1007/BF01221192.

Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells.

Cancer Chemother Pharmacol. 1996;37(5):457-62. doi: 10.1007/s002800050412.

Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines.

Br J Cancer. 1995 Apr;71(4):684-90. doi: 10.1038/bjc.1995.135.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

The molecular basis of cisplatin sensitivity/resistance.

作者信息

Kelland L R

机构信息

Section of Drug Development, Institute of Cancer Research, Sutton, Surrey, U.K.

出版信息

Eur J Cancer. 1994;30A(6):725-7. doi: 10.1016/0959-8049(94)90281-x.

DOI:10.1016/0959-8049(94)90281-x

PMID:7917526

Abstract

摘要

相似文献

The molecular basis of cisplatin sensitivity/resistance.

Eur J Cancer. 1994;30A(6):725-7. doi: 10.1016/0959-8049(94)90281-x.

Assessment of platinum sensitivity in human tumor cells.

Int J Clin Pharmacol Ther. 2003 Dec;41(12):612-3. doi: 10.5414/cpp41612.

Gene expression in X-irradiated human tumour cell lines expressing cisplatin resistance and altered DNA repair capacity.

Carcinogenesis. 1994 Sep;15(9):2053-6. doi: 10.1093/carcin/15.9.2053.

Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.

Cancer Res. 1992 Apr 1;52(7):1710-6.

Genetic basis of drug sensitivity in human testis tumour cells.

Int J Cancer. 1996 Feb 8;65(4):426-31. doi: 10.1002/(SICI)1097-0215(19960208)65:4<426::AID-IJC5>3.0.CO;2-Z.

Complementation analysis of testis tumor cells.

Cancer Genet Cytogenet. 1997 Oct 1;98(1):56-62. doi: 10.1016/s0165-4608(96)00398-6.

Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells.

Proc Natl Acad Sci U S A. 1988 Feb;85(3):650-3. doi: 10.1073/pnas.85.3.650.

Single step selection of cis-diamminedichloroplatinum(II) resistant mutants from a human ovarian carcinoma cell line.

Cancer Res. 1991 Apr 15;51(8):2242-5.

[Quantitative determination of dose-response relations of taxol and cisplatin in ovarian cancer cells with a bioassay in comparison with cytomorphology].

Gynakol Geburtshilfliche Rundsch. 1994;34(2):79-86. doi: 10.1159/000272342.

Metallothionein gene expression and resistance to cisplatin in human ovarian cancer.

Int J Cancer. 1990 Mar 15;45(3):416-22. doi: 10.1002/ijc.2910450306.

引用本文的文献

DFT Study on the Substituent Effect of Anticancer Picoline-Diazido-Pt(IV) Compounds.

Front Oncol. 2022 Jan 10;11:749178. doi: 10.3389/fonc.2021.749178. eCollection 2021.

Contributes to Cell Cycle Progression and Cisplatin Resistance.

Cancers (Basel). 2021 Aug 12;13(16):4066. doi: 10.3390/cancers13164066.

Trans labilization of am(m)ine ligands from platinum(II) complexes by cancer cell extracts.

J Biol Inorg Chem. 2009 Mar;14(3):387-99. doi: 10.1007/s00775-008-0456-6. Epub 2008 Dec 4.

Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei.

Nucleic Acids Res. 2006 Mar 29;34(6):e47. doi: 10.1093/nar/gkl051.

The trans labilization of cis-[PtCl2(13CH3NH2)2] by glutathione can be monitored at physiological pH by [1H,13C] HSQC NMR.

J Biol Inorg Chem. 2006 Mar;11(2):179-88. doi: 10.1007/s00775-005-0064-7. Epub 2005 Dec 10.

A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts.

Br J Cancer. 1999 Aug;80(12):1912-9. doi: 10.1038/sj.bjc.6690620.

Cell-cycle arrest, micronucleus formation, and cell death in growth inhibition of MCF-7 breast cancer cells by tamoxifen and cisplatin.

J Cancer Res Clin Oncol. 1996;122(10):603-12. doi: 10.1007/BF01221192.

Cross-resistance and collateral sensitivity to natural product drugs in cisplatin-sensitive and -resistant rat lymphoma and human ovarian carcinoma cells.

Cancer Chemother Pharmacol. 1996;37(5):457-62. doi: 10.1007/s002800050412.

Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines.

Br J Cancer. 1995 Apr;71(4):684-90. doi: 10.1038/bjc.1995.135.